Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma

Abstract Background Metastatic urothelial carcinoma (mUC) has a poor prognosis, despite recent therapeutic advancements. Prostaglandin Reductase 1 (PTGR1) is essential for activating acylfulvens, a promising class of drugs for treating a subset of urothelial carcinoma (UC) patients. The efficacy of...

Descrición completa

Detalles Bibliográficos

Principais autores:	Dag Rune Stormoen, Signe Lehn, Kent W. Mouw, Zoltan Szallasi, Linea Cecilie Melchior, Line Hammer Dohn, Judit Börcsok, Maria Rossing, Birgitte Grønkaer Toft, Helle Pappot
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2024-11-01
Series:	Scientific Reports
Assuntos:	Bladder cancer Urothelial cancer Biomarker Validation study DNA repair deficiency PTGR1
Acceso en liña:	https://doi.org/10.1038/s41598-024-79334-x
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!